Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
CANCER:
Male Breast Cancer
Associations
(10)
News
Trials
A2 | Sensitive
B | Sensitive
C3 | Sensitive
A2 | Resistant
B | Resistant
C3 | Resistant
Show legend
Group by Gene:
Drug categories
Hormone Therapy
Tyrosine Kinase Inhibitors
Other
PI3 Kinase Inhibitors
Cyclin Dependent Kinase Inhibitors
Serine-Threonine Kinase Inhibitors
CD Protein Inhibitors
Cancel
Estrogen receptor antagonist
tamoxifen
PIK3CA inhibitor
alpelisib
Selective estrogen receptor degrader
fulvestrant
CDK4 inhibitor + CDK6 inhibitor
CDK4 inhibitor, CDK6 inhibitor
ribociclib
palbociclib
Aromatase inhibitor
Aromatase inhibitor
HER2 inhibitor
HER2 inhibitor
No biomarker
A2
No biomarker
|
Male Breast Cancer
|
HER2 inhibitor
HR positive + HER-2 negative
A2
HR positive + HER-2 negative
|
Male Breast Cancer
|
tamoxifen
A2
HR positive + HER-2 negative
|
Male Breast Cancer
|
fulvestrant
C3
HR positive + HER-2 negative
|
Male Breast Cancer
|
CDK4 inhibitor + CDK6 inhibitor
B
HR positive + HER-2 negative
|
Male Breast Cancer
|
ribociclib
C3
HR positive + HER-2 negative
|
Male Breast Cancer
|
palbociclib
PIK3CA mutation + HR positive + HER-2 negative
A2
PIK3CA mutation + HR positive + HER-2 negative
|
Male Breast Cancer
|
alpelisib
HR positive
A2
HR positive
|
Male Breast Cancer
|
tamoxifen
A2
HR positive
|
Male Breast Cancer
|
Aromatase inhibitor
ER positive
A2
ER positive
|
Male Breast Cancer
|
tamoxifen
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
